WallStreetZenWallStreetZen

NASDAQ: GLMD
Galmed Pharmaceuticals Ltd Stock

Open Broker Account
$0.29+0.00 (+0%)
Updated Dec 8, 2022
GLMD Price
$0.29
Fair Value Price
$0.45
Market Cap
$7.31M
52 Week Low
$0.29
52 Week High
$2.38
P/E
-0.32x
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.33
Operating Cash Flow
-$21M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GLMD Overview

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GLMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GLMD ($0.29) is undervalued by 35.74% relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GLMD ($0.29) is significantly undervalued by 35.74% relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLMD due diligence checks available for Premium users.

Be the first to know about important GLMD news, forecast changes, insider trades & much more!

GLMD News

Valuation

GLMD fair value

Fair Value of GLMD stock based on Discounted Cash Flow (DCF)
Price
$0.29
Fair Value
$0.45
Undervalued by
35.74%
GLMD ($0.29) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLMD ($0.29) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GLMD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.32x
Industry
13.31x
Market
21.39x

GLMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.98x
GLMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GLMD's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
GLMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$20.9M
Liabilities
$5.1M
Debt to equity
0.33
GLMD's short-term assets ($20.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLMD's short-term assets ($20.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GLMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.1M
Investing
$5.1M
Financing
$70.0k
GLMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GLMD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GLMD$7.31M-1.36%-0.32x0.46x
PTIX$7.55M+1.63%-1.99x1.02x
ATXI$6.97M-1.35%-0.39x-178.69x
ADTX$6.95M-1.18%-0.02x0.55x
KALA$7.71M+2.83%-0.09x-7.97x

Galmed Pharmaceuticals Stock FAQ

What is Galmed Pharmaceuticals's quote symbol?

NASDAQ: GLMD) Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol GLMD. Galmed Pharmaceuticals stock quotes can also be displayed as NASDAQ: GLMD.

If you're new to stock investing, here's how to buy Galmed Pharmaceuticals stock.

What is the 52 week high and low for Galmed Pharmaceuticals (NASDAQ: GLMD)?

(NASDAQ: GLMD) Galmed Pharmaceuticals's 52-week high was $2.38, and its 52-week low was $0.29. It is currently -87.82% from its 52-week high and at its 52-week low.

How much is Galmed Pharmaceuticals stock worth today?

(NASDAQ: GLMD) Galmed Pharmaceuticals currently has 25,203,396 outstanding shares. With Galmed Pharmaceuticals stock trading at $0.29 per share, the total value of Galmed Pharmaceuticals stock (market capitalization) is $7.31M.

Galmed Pharmaceuticals stock was originally listed at a price of $14.31 in Mar 13, 2014. If you had invested in Galmed Pharmaceuticals stock at $14.31, your return over the last 8 years would have been -97.97%, for an annualized return of -38.58% (not including any dividends or dividend reinvestments).

How much is Galmed Pharmaceuticals's stock price per share?

(NASDAQ: GLMD) Galmed Pharmaceuticals stock price per share is $0.29 today (as of Dec 8, 2022).

What is Galmed Pharmaceuticals's Market Cap?

(NASDAQ: GLMD) Galmed Pharmaceuticals's market cap is $7.31M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Galmed Pharmaceuticals's market cap is calculated by multiplying GLMD's current stock price of $0.29 by GLMD's total outstanding shares of 25,203,396.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.